- 65 Downloads
Diabetes mellitus is a major risk factor for the development of congestive heart failure (CHF). Diabetic cardiomyopathy has been acknowledged as a distinct disease entity that is an additional risk for diabetic patients to develop CHF, especially when they are affected by hypertension or epicardial coronary artery disease. Moreover, diabetic cardiomyopathy has been documented to lead to CHF even in the absence of other risk factors. As the combination of hypertension and diabetes has shown to be particularly detrimental, aggressive blood pressure control with a goal of less than 130/85 mm Hg is of critical importance. The first choice for pharmacologic treatment is angiotensinconverting enzyme inhibitors. Double- or triple-drug therapy is frequently required for good control. The increased risk of epicardial coronary artery disease in patients with diabetes warrants stringent treatment of dyslipidemia. If dilated cardiomyopathy with low ejection fraction is present, therapy with angiotensin-converting enzyme inhibitors, digoxin, diuretics, beta-blockers, and spironolactone (for patients with New York Heart Association class III to IV functional status) is indicated. If cardiac dysfunction consists predominantly of impaired diastolic function, heart rate control with a beta-blocker or a calcium antagonist is of particular importance. Control of blood glucose should be achieved, with hemoglobin A1c levels of less than 7%. Hyperinsulinemia should be avoided when possible; therefore, insulin-sensitizing agents are preferred over insulin-secretion-enhancing agents. Symptoms of CHF and acutely decompensated CHF should be treated no differently than nondiabetic patients. Care for patients with diabetes always includes lifestyle changes consisting of smoking cessation, decreasing obesity, regular exercise, and a heart-healthy diabetic diet.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Pailolle C, Dahan M, Paycha F, et al.: Prevalence and significance of left ventricular filling abnormalities determined by Doppler echocardiography in young type I (insulin-dependent) diabetic patients. Am J Cardiol 1990, 64:1100–1106.Google Scholar
- 6.Grady KL, Dracup K, Kennedy G, et al.: Team management of patients with heart failure: a statement for healthcare professionals from The Cardiovascular Nursing Council of the American Heart Association. Circulation 2000, 102:2443–2456. Practical advice for providing guidance and assistance for patients with CHF.PubMedGoogle Scholar
- 7.Long BJ, Calfas KJ, Wooten W, et al.: A multisite field test of the acceptability of physical activity counseling in primary care: project PACE. Am J Prev Med 1996, 12:73–81. The PACE (Physician-based Assessment and Counseling for Exercise) program assists health-care providers in overcoming barriers to counseling patients about physical activity. The PACE program is potentially an importanat part of a national effort to enhance the adoption and maintenance of physical activity among adults.PubMedGoogle Scholar
- 10.Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355:253-259.Google Scholar
- 11.Young JB, Gheorghiade M, Uretsky BF, et al.: Superiority of “triple” drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Prospective Randomized Study of Ventricular Function and Efficacy of Digoxin. Randomized Assessment of Digoxin and Inhibitors of Angiotensin-Converting Enzyme. J Am Coll Cardiol 1998, 32:686–692. A prospective clinical trial in patients with symptomatic CHF investigating four treatment regimens: 1) diuretics alone, 2) digoxin and diuretics, 3) ACE inhibitors and diuretics, or 4) digoxin, diuretic, and ACE inhibitor. The data analysis suggested that triple-drug therapy is superior to other drug regimens in decreasing worsening of cardiac function.PubMedCrossRefGoogle Scholar
- 16.Packer M, Coats AJ, Fowler MB, et al.: Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651–1658. This prospective trial used beta-blockers in the treatment of patients with severe heart failure, and showed benefit in regard to morbidity and mortality.PubMedCrossRefGoogle Scholar
- 17.Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717. A prospective trial showing that the use of spironolactone in medical regimens for patients with severe CHF decreased hospital admissions and improved clinical symptoms.PubMedCrossRefGoogle Scholar
- 18.Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) study group. BMJ 1997, 314:1512–1515.PubMedGoogle Scholar
- 19.Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD investigators. N Engl J Med 1992, 327:685-691.Google Scholar
- 23.Giles TD, Katz R, Sullivan JM, et al.: Short- and longacting angiotensin-converting enzyme inhibitors: a randomized trial of lisinopril versus captopril in the treatment of congestive heart failure. The Multicenter Lisinopril-Captopril Congestive Heart Failure Study Group. J Am Coll Cardiol 1989, 13:1240–1247.PubMedCrossRefGoogle Scholar
- 25.The effects of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997, 336:525-533.Google Scholar
- 28.Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 1996, 335:217-225.Google Scholar